Unsolved problems and future perspectives of hepatitis B virus vaccination
Kazuto Tajiri,Yukihiro Shimizu +1 more
Reads0
Chats0
TLDR
The necessity, timing and method of booster vaccination in responders with decreased anti-HBs responses, and effective vaccination against S-mutant HBV, are issues requiring resolution in the global prevention of HBV infection.Abstract:
Hepatitis B virus (HBV) infection is still a serious worldwide problem, and vaccination is the most effective strategy for primary prevention of the infection. Although universal vaccination may be required for total eradication, several countries, including Japan, have not yet adopted universal vaccination programs. Some individuals are non-responders to HBV vaccine and several mechanisms responsible for their poor response have been proposed. To overcome non-response, third generation vaccines with pre-S proteins have been developed. These vaccines have shown better anti-HBs responses and may also be effective in preventing infection by HBV with S mutant. Improvement of vaccine efficacy by intradermal administration, or co-administration with cytokines or adjuvants, may also be effective in non-responders. The necessity, timing and method of booster vaccination in responders with decreased anti-HBs responses, and effective vaccination against S-mutant HBV, are issues requiring resolution in the global prevention of HBV infection.read more
Citations
More filters
Journal ArticleDOI
Three decades of hepatitis B control with vaccination.
TL;DR: For the last three decades, 179 countries have added HBV vaccination to their routine vaccination programs with great results as discussed by the authors, which can lead to acute liver failure, acute hepatitis, chronic carriership, chronic hepatitis of HBV, liver cirrhosis, liver cancer, liver transplantation and death.
Journal Article
A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients. Commentary
J. K. Unger,H. Peters,Norella C T Kong,Jiri Beran,S. A. Kee,J. L. Miguel,C. Sanchez,J.-M. Bayas,Anna Vilella,F. Calbo-Torrecillas,E. Lopez De Novales,Karthik Srinivasa,Michel Stoffel,Bernard Hoet +13 more
TL;DR: In this population of prehemodialysis and hemodialysis patients, the HBV-AS04 was immunogenic, safe, and well-tolerated both as a booster dose after HBV -AS04 or standard hepatitis B vaccine priming.
Journal ArticleDOI
Hepatitis B Vaccine and Immunoglobulin: Key Concepts
Saibal Das,Kirubakaran Ramakrishnan,Sapan Kumar Behera,Mahalakshmi Ganesapandian,Alphienes Stanley Xavier,Sandhiya Selvarajan +5 more
TL;DR: The response of the host immune system to HBV vaccination (immunogenicity), efficacy, and safety of the vaccine, issues with booster dosing, paths of development (preclinical and clinical) of the HBV vaccine, novel and upcoming strategies for improvement ofHBV vaccination, and the concept of therapeutic HBV vaccinations are highlighted.
Journal ArticleDOI
Oral hepatitis B vaccine: chitosan or glucan based delivery systems for efficient HBsAg immunization following subcutaneous priming
TL;DR: Two distinct and promising delivery systems were developed: recombinant hepatitis B surface antigen encapsulated into alginate-coated chitosan particles (AlgChiPs) and into glucan particles(GPs) mainly composed of β-1,3-d-glucan, which showed interesting immunostimulating properties as mast cells activators.
Journal ArticleDOI
Persistence of Immunity for Hepatitis B Virus among Heathcare Workers and Italian Medical Students 20 Years after Vaccination
Luca Coppeta,Andrea Pompei,Ottavia Balbi,Ludovico Maria De Zordo,Federica Mormone,Sara Policardo,Piergiorgio Lieto,Antonio Pietroiusti,Andrea Magrini +8 more
TL;DR: A substantial percentage of HCWs had a non-protective anti-HBs titer at the time of the first employment, especially those vaccinated at birth age, therefore, primary immunization in childhood is highly effective and provides lasting immunity against HBV infection.
References
More filters
Journal ArticleDOI
Estimating the world cancer burden: Globocan 2000
TL;DR: GLOBOCAN 2000 updates the previous data-based global estimates of incidence, mortality and prevalence to the year 2000 and uses a “databased” approach, rather different from themodeling method used in other estimates.
Journal ArticleDOI
Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures
TL;DR: More efficacious treatments, mass immunization programs, and safe injection techniques are essential for eliminating HBV infection and reducing global HBV‐related morbidity and mortality.
Journal ArticleDOI
Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group.
Mei-Hwei Chang,Chien-Jen Chen,Mei-Shu Lai,Hsu-Mei Hsu,Tzee-Chung Wu,Man-Shan Kong,Der-Cherng Liang,Wen-Yi Shau,Ding-Shinn Chen +8 more
TL;DR: The incidence of hepatocellular carcinoma in children in Taiwan from 1981 to 1994 has declined since the institution of Taiwan's program of universal hepatitis B vaccination, and the corresponding rates of mortality have decreased.
Journal ArticleDOI
Vaccine-induced escape mutant of hepatitis B virus
William F. Carman,Peter Karayiannis,Jenny Waters,Howard C. Thomas,Alessandro Zanetti,G. Manzillo,Arie J. Zuckerman +6 more
TL;DR: In southern Italy, 44 contacts of hepatitis B virus carriers, including infants of carrier mothers, became HBsAg positive despite passive and active immunisation according to standard protocols, and infection was confirmed by the presence of additional markers of viral replication.
Journal ArticleDOI
Human hepatitis B vaccine from recombinant yeast
William J. McAleer,Buynak Eb,R Z Maigetter,D E Wampler,William J. Miller,Maurice R. Hilleman +5 more
TL;DR: This is the first example of a vaccine produced from recombinant cells which is effective against a human viral infection, and the purified antigen in alum formulation stimulated production of antibody in mice, grivet monkeys and chimpanzees.